VYNE Therapeutics (VYNE) Stock: Buy, Sell, or Hold?
VYNE - VYNE Therapeutics Inc. Common Stock
$28.56
28.05 (5511.00%)
â˛
5d:
+3435.53%
30d:
+4282.38%
90d:
+4327.22%
WAIT
LOW Confidence
Analysis Updated: Jul 27, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When VYNE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: VYNE is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: VYNE is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: VYNE is currently trading at $28.56, which is considered fair based on recent price action.
Technical Outlook: Technically, VYNE is in a strong downtrend. The price is approaching resistance at $28.56. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5511.0% recently.
Market Sentiment: VYNE scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. However, the stock is trading significantly above the average Wall Street target of $2.00. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, VYNE is in a strong downtrend. The price is approaching resistance at $28.56. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5511.0% recently.
Market Sentiment: VYNE scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. However, the stock is trading significantly above the average Wall Street target of $2.00. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
39/100
(SELL)
Volume Confirmation
UNKNOWN
Confidence Score
76.3%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: Strong upward momentum (+5511.0%)
- BEARISH: Trading 93.0% above Wall St target ($2.00)
- WARNING: Composite score 39/100 in the bottom quintile â this cohort historically lags the market
Support & Resistance Levels
Support Level
$0.47
Resistance Level
$28.56
Current Trend
Strong Downtrend
Technical data as of
Jul 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.35
Wall Street Target
$2.00
(-93.0%)
Revenue Growth (YoY)
-57.4%
Share & Embed Analysis
Last updated: September 13, 2026 8:58 PM ET
Data refreshes hourly during market hours. Next update: 9:58 PM
Data refreshes hourly during market hours. Next update: 9:58 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VYNE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$128 | 50 HOLD |
|
JSPR
Jasper Therapeutics Inc |
STRONG BUY
11 analysts |
$7 | 62 BUY |
|
RLAY
Relay Therapeutics Inc |
STRONG BUY
13 analysts |
$27 | 64 BUY |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$37 | 44 HOLD |
